1-(2-((Z)-6-(2-(trifluoromethyl)phenyl)hexa-3-en-1,5-diynyl)phenyl) -piperidin-2-one as a new potent apoptosis agent

Bioorganic and Medicinal Chemistry

Volumn 17, Issue 21, 2009, Pages 7412-7417

  Tu, Yu Sheng ^a   Duh, Tsai Hui ^a   Tseng, Chen Yi ^b   Lin, Ying Ting ^a   Lo, Yu Hsiang ^a   Hu, Yi Ling ^a   Chen, Chen Hung ^a   Chien, Ching Ming ^a   Yang, Sheng Huei ^a   Lin, Shinne Ren ^a   Yang, Shyh Chyun ^a   Wu, Ming Jung ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Acyclic enediynes; Anti tubulin; Antitumor agents; Apotosis

Indexed keywords

1 [2(6 (2 (TRIFLUOROMETHYL)PHENYL)HEX 3 EN 1,5 DIYNYL)PHENYL]PIPERIDIN 2 ONE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CYTOCHROME C; PIPERIDINE DERIVATIVE; PROTEIN BAX; PROTEIN BCL 2; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS; 1 (2 ((Z) 6 (2 (TRIFLUOROMETHYL)PHENYL)HEXA 3 EN 1,5 DIYNYL)PHENYL)PIPERIDIN 2 ONE; 1-(2-((Z)-6-(2-(TRIFLUOROMETHYL)PHENYL)HEXA-3-EN-1,5-DIYNYL)PHENYL)PIPERIDIN-2-ONE; PIPERIDONE DERIVATIVE; TUBULIN MODULATOR;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; TUMOR CELL LINE; WESTERN BLOTTING; CELL DIVISION; CHEMISTRY; DRUG SCREENING; HELA CELL; METABOLISM; SYNTHESIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL DIVISION; CELL LINE, TUMOR; CYTOCHROMES C; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE; HELA CELLS; HUMANS; PIPERIDONES; PROTO-ONCOGENE PROTEINS C-BCL-2; TUBULIN MODULATORS;

EID: 73949114945     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2009.09.042     Document Type: Article

References (14)

1. (a) Jordan, M. A.; Wilson, L. Curr. Opin. Cell Biol. 1998, 10, 123
2. (b) Jordan, M. A.; Wilson, L. Nat. Rev. Cancer 2004, 4, 253.
3. Schiff, P. B.; Fant, J.; Horwitz, S. B. Nature 1979, 277, 665.
4. Li, Q.; Sham, H.; Rosenberg, S. Ann. Rep. Med. Chem. 1999, 34, 139.
5. Nam, N. H. Curr. Med. Chem. 2003, 10, 1697.
6. Jordan, M. A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Med. Res. Rev. 1998, 18, 259.
7. Mahboobi, S.; Pongratz, H.; Hufsky, H.; Hockemeyer, J.; Frieser, M.; Lyssenko, L.; Paper, D. H.; Bürgermeister, J.; Böhmer, F. D.; Fiebig, H. H.; Burger, A. M.; Baasner, S.; Beckers, T. J. Med. Chem. 2001, 44, 4535.
8. (a) Lo, Y. H.; Lin, C. C.; Lin, C. F.; Lin, Y. T.; Duh, T. H.; Hong, Y. R.; Yang, S. H.; Lin, S. R.; Yang, S. C.; Chang, L S.; Wu, M. J. J. Med. Chem. 2008, 51, 2682
9. (b) Lin, C. F.; Lo, Y. H.; Hsieh, M. C.; Chen, Y. H.; Wang, J. J.; Wu, M. J. Bioorg Med. Chem. 2005, 13, 3565.
10. Boyd, M. R.; Paull, K. D. Drug Dev. Res. 1995, 34, 91.
11. Horvitz, H. R. ChemBioChem 2003, 4, 697.
12. Daniel, P. T.; Koert, U.; Schuppan, J. Angew. Chem., Int. Ed. 2006, 45, 872.
13. Wu, Z. Z.; Chien, C. M.; Yang, S. H.; Lin, Y. H.; Hu, X. W.; Lu, Y.J.; Wu, M.J.; Lin, S. R. Mol. Cell. Biol. 2006, 292, 99.
14. Lin, C. C.; Cheng, T. S.; Hsu, C. M.; Wu, C. H.; Chang, L S.; Shen, Z. S.; Yeh, H. M.; Chang, L. K.; Howng, S. L; Hong, Y. R. Cell Cycle 2006, 5, 2517.